Over the past 10 years, I have successfully been working in the oncology field, having the opportunity to work with high-quality and well-recognized research groups in National Cancer Institute in Naples (Italy), Centro Nacional de Investigaciones Oncologicas (CNIO, Madrid), where I obtained my PhD, and Weill Cornell Medical College (WCMC, New York) where I’m working as senior postdoctoral associate.
My research has been focused on the discovery of new molecular targets within tumor samples from pancreatic, renal, ovarian and prostate cancer patients, in order to develop effective combinational treatments and improve the clinical outcome. Specifically, I have identified new therapeutic approaches able to eliminate cancer stem cells with a special focus on preclinical models, that can be used for personalized medicine. More recently I have been involved in developing pancreatic, prostate and colon cancer organoids from patient biopsies and isolating exosomes to identify specific diagnostic and prognostic biomarkers. This system also allow us to study new therapeutic combinations of drugs using preclinical models (organoids and PDXs) and functional validation in precision medicine for pancreatic, prostate and colon cancer.